Latest News

If you are wondering whether Lumen Technologies at US$6.83 is a bargain or a value trap, you are in the right place as we unpack what the current price really implies. The stock has been volatile, with a 3% decline over the last 7 days, a 19.3% decline over the last 30 days, an 11.2% decline year to date and a 35.8% return over the last year. Recent attention on Lumen has included ongoing discussions about its debt load, refinancing efforts and long term business transformation plans. These...

What Cochlear’s Nucleus Nexa launch could mean for shareholders Cochlear (ASX:COH) has launched its Nucleus Nexa System, a smart cochlear implant with upgradeable firmware and built in memory, now available in India from March 1, 2026. This product launch adds another option to Cochlear’s implantable hearing solutions portfolio, giving investors a fresh event to consider alongside the company’s current share price and recent share performance. See our latest analysis for Cochlear. Despite...

If you are wondering whether Cognex is still good value after a strong run, you are not alone. This article will walk through what the current share price might be implying. The stock has had a mixed ride, with a 7.4% decline over the last 7 days, a 25.5% gain over 30 days, 38.8% year to date and 58.4% over the past year, while the 3 year return sits at 8.6% and the 5 year return at a 34.1% decline. These swings have put a spotlight on Cognex as investors react to recent company specific...

Idorsia reports recent commercial traction for its insomnia drug Quvivic, including broader public reimbursement across major European and North American markets. The company highlights plans for further international rollout of Quvivic and updates on late stage pipeline assets, including pediatric studies. Partnered programs are progressing clinically, with collaborations moving forward alongside Idorsia’s own R&D efforts. Idorsia (SWX:IDIA) is drawing attention as it updates investors on...

Why Trump Media & Technology Group (DJT) is Back in Focus Trump Media & Technology Group (DJT) is drawing fresh attention after reporting full year 2025 results, showing US$3.68 million in sales and a net loss of US$712.06 million, alongside plans for a merger with TAE Technologies and a Truth Social spin off. See our latest analysis for Trump Media & Technology Group. The 1 month share price return of 11.89% and year to date share price return of 22% declines, alongside a 1 year total...

Xenia Hotels & Resorts (NYSE:XHR) reports broad-based revenue gains across its portfolio alongside margin expansion. The company points to a successful ramp-up at its Scottsdale property as a key contributor to recent performance. Management highlights ongoing aggressive share repurchases, a newly authorized buyback plan, and a sharpened focus on deleveraging. These moves reflect an evolution in capital allocation priorities that goes beyond routine earnings and dividend updates. Xenia...

Earnings shock and housing platform moves put Rocket Companies (RKT) in focus Rocket Companies (RKT) is back on investors' radar after its 2025 earnings update, which paired strong revenue figures and new housing partnerships with a full year net loss and sharp share price pressure. See our latest analysis for Rocket Companies. The share price reaction has been rough in the short term, with a 1 day share price return of a 5.83% decline and a 30 day share price return of a 23.05% decline as...

Topaz Energy Corp. recently reported its 2025 results, with revenue rising to C$357.84 million and net income reaching C$128.74 million, alongside higher royalty production across natural gas, crude oil, and NGLs. The company also reaffirmed its income focus by declaring a C$0.34 per-share dividend for first-quarter 2026 and issuing 2026 royalty production guidance broadly in line with its expanded 2025 production base. We’ll now examine how the stronger royalty production and confirmed...

PG&E (NYSE:PCG) has declared its regular cash dividend for the first quarter of 2026. The decision reflects the board's current capital return policy and provides an update on shareholder payouts. The announcement comes with PG&E shares trading at $18.13. For investors watching NYSE:PCG, the new dividend declaration adds another piece of information to consider alongside recent share performance. The stock is priced at $18.13 and has logged a 30 day return of 18.2%, with gains of 11.4% year...

Seadrill (SDRL) has drawn fresh attention after announcing seven new rig contracts worth about US$0.5b in added backlog, along with 2026 guidance for operating revenue and adjusted EBITDA that gives investors clearer forward-looking earnings markers. See our latest analysis for Seadrill. The latest rig awards and 2026 guidance arrive after a period of strong momentum, with a 30 day share price return of 12.66% and a 90 day share price return of 36.56%, while the 1 year total shareholder...

In early March 2026, Century Aluminum Company disclosed it would miss the SEC deadline for filing its 2025 Form 10-K due to an accounting change related to its majority-owned Jamalco joint venture, although the shift does not affect net income, non-GAAP metrics, or debt covenants. At the same time, Century Aluminum’s joint development agreement with Emirates Global Aluminium to build a new U.S. smelter highlights how the company is reshaping its production footprint while addressing...

If you are wondering whether Houlihan Lokey's current share price really lines up with its underlying worth, you are in the right place. This article will walk through what the numbers actually say about value. The stock closed at US$157.30, with returns of a 7% decline over the past week, a 4.3% decline over the past month, a 10.8% decline year to date, but a 1.3% gain over 1 year, 83.3% over 3 years and 153.1% over 5 years. This performance can naturally raise questions about how much...

Why George Weston Is On Investors’ Radar Today George Weston (TSX:WN) has recently drawn attention after a mixed run in its share performance, with the stock showing a 1.5% decline over the past day and a 5.7% decline over the past week. See our latest analysis for George Weston. That short stretch of weaker share price returns, including the recent 7 day and 30 day declines, sits alongside a much stronger picture over time. The 1 year total shareholder return of 19.8% and a 5 year total...

Wondering whether Iridium Communications' share price reflects its true worth, or if the market is missing something that you could be seeing instead? The stock last closed at US$23.95, with recent returns of 6.5% over 7 days, 22.1% over 30 days and 34.9% year to date. The 1‑year return sits at an 18.8% decline, and the 3‑ and 5‑year returns are 57.3% and 39.2% declines respectively. Recent attention on Iridium Communications has been driven less by a single headline and more by ongoing...

If you are wondering whether Plains GP Holdings is still good value after its recent run, this article walks through what the current price might be implying about the business. The stock last closed at US$23.70, with returns of 6.8% over 7 days, 12.3% over 30 days, 22.1% year to date, 26.1% over 1 year, and a very large gain over 5 years. Recent coverage has focused on Plains GP Holdings as an energy infrastructure player that continues to attract attention, with investors watching how it...

If you are wondering whether EPR Properties is offering good value at its current price, this article will walk you through what the numbers are really saying about the stock. The shares last closed at US$57.56, with returns of 4.0% over 30 days, 13.4% year to date, 16.4% over 1 year, 83.3% over 3 years, and 67.3% over 5 years. These figures may influence how investors think about both its potential and its risks. Recent attention on EPR Properties has centered on its positioning as a real...

PagSeguro Digital (NYSE:PAGS) has just wrapped up FY 2025 with Q4 revenue of R$5.2b and basic EPS of R$1.74, alongside net income of R$502.0m. These figures put fresh numbers on the table for investors watching its profitability profile. Over recent periods, the company has seen revenue move from R$5.0b in Q4 2024 to R$5.2b in Q4 2025, while basic EPS shifted from R$1.93 to R$1.74. Trailing twelve month EPS stands at R$7.18 on revenue of R$19.7b and net income of R$2.1b, setting the context...

CStone Pharmaceuticals previously announced that the UK MHRA has granted a new indication for sugemalimab monotherapy in certain adult patients with unresectable stage III non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiotherapy. This adds to approvals by the European Commission and UK MHRA across multiple non-small cell lung cancer settings, potentially broadening sugemalimab’s clinical footprint in key international markets. We will now examine how...

AppFolio recently outlined that revenue growth is outpacing customer additions as users adopt more paid services, supporting higher free-cash-flow margins and a broader mix of income streams, including services sold directly to residents on its platform. Management’s guidance for 2026, including revenue of about US$1.10 billion and a larger adjusted operating margin near 26.5%, highlights how operating leverage and deeper monetization per unit are reshaping the company’s profit...

Bayer FY 2025 earnings snapshot Bayer (XTRA:BAYN) has capped FY 2025 with a tough final quarter, posting Q4 revenue of €11.4 billion and a basic EPS loss of €3.80, alongside a net loss of €3.8 billion. Over recent periods, the company has seen quarterly revenue move between €9.7 billion and €13.7 billion, while EPS has swung from a profit of €1.32 in Q1 2025 to losses in each of the following quarters. This keeps the focus firmly on how quickly margins can stabilize. With forecasts in the...

What Savaria’s latest earnings signal for investors Savaria (TSX:SIS) just reported record 2025 results, including its highest quarterly EBITDA, full year revenue of CA$913.53 million, and net income of CA$68.77 million, closing out its two year Savaria One transformation program. Earnings per share from continuing operations reached CA$0.96 on a basic basis and CA$0.95 on a diluted basis, while both the Accessibility and Patient Care segments contributed to the stronger full year...

If you are wondering whether Atlantic Union Bankshares is offering fair value at its current share price, this article walks through what the numbers are really saying about the stock. The shares most recently closed at US$36.56, with returns of 2.9% year to date and 14.2% over 1 year, while the past 7 days and 30 days have seen declines of 7.5% and 9.8% respectively. Recent moves in regional bank stocks, including Atlantic Union Bankshares, have been shaped by ongoing headlines around...

CSL (ASX:CSL) is back in focus after two fresh developments: a larger on market share buy back now covering nearly four million shares, and a new Canadian pandemic influenza vaccine contract for CSL Seqirus. See our latest analysis for CSL. Despite the fresh buy back and the Canadian vaccine contract, CSL's share price has had a weak patch, with a 30 day share price return of 19.5% and a 1 year total shareholder return decline of 42.6%, pointing to fading momentum after several tougher...

If you are wondering whether Concentrix is a bargain or a value trap at around US$34.50 per share, looking closely at its valuation story is a good place to start. The stock has recently shown a 7.6% gain over the last 7 days, but that comes after weaker returns of a 7.5% decline over 30 days, a 16.3% decline year to date, a 20.4% decline over 1 year, and 72.8% and 73.6% declines over 3 and 5 years respectively. These moves have been happening alongside ongoing attention on Concentrix as a...